Clearance Concepts: Fundamentals and Application to Pharmacokinetic Behavior of Drugs

Abstract

Clearance concepts were introduced into the pharmacokinetics discipline in the 1970s and since then have played a major role in characterization of the pharmacokinetic behavior of drugs. These concepts are based on the relationship between organ extraction ratio or clearance and physiologic parameters such as the organ blood flow and the intrinsic capability of the eliminating organ to remove the free (unbound) drug from the body. Several theoretical models have been developed, which define these relationships and may be used to predict the effects of changes in the physiological parameters on various pharmacokinetic parameters of drugs, such as drug clearance. In this communication, the fundamentals of the two most widely used models of hepatic metabolism, namely the well-stirred (venous equilibrium) and parallel-tube (sinusoidal perfusion) models, are reviewed. Additionally, the assumptions inherent to these models and the differences between them in terms of their predictive behavior are discussed. The effects of changes in the physiologic determinants of clearance on the blood concentration-time profiles of drugs with low and high extraction ratio are also presented using numerical examples. Lastly, interesting and unusual examples from the literature are provided where these concepts have been applied beyond their widely known applications. These examples include estimation of the oral bioavailability of drugs in the absence of otherwise needed intravenous data, differentiation between the role of liver and gut in the first-pass loss of drugs, and distinction between the incomplete absorption and first-pass metabolism in the gastrointestinal tract after the oral administration of drugs. It is concluded that the clearance concepts are a powerful tool in explaining the pharmacokinetics of drugs and predicting the changes in their blood concentration-time courses when the underlying physiologic parameters are altered due to age, disease states, or drug interactions. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

Stereochemical facets of clinical β‐blockers: An overview

“…All marketed modern β‐blockers possess one or more than one chiral center in their framework. The chirality recognition is a vital aspect in deducing the interaction of β‐blockers with β‐adrenoreceptors, as it is extremely stereospecific . β‐blockers are among the important class of drugs studied for their stereochemical facets.…”

“…Being basic drugs, the β ‐ blockers are capable of binding to both albumin and α1‐glycoprotein in the plasma . As the proteins are chiral in nature, the binding of β‐blockers may be stereoselective.…”

Desymmetrization of meso diols using enantiopure zinc (II) dimers: Synthesis and chiroptical properties

“…Such diols are widely used in their symmetrical and unsymmetrical forms as building blocks in various pharma and organic compounds . Nadolol, the well‐known β‐blocker, contains a meso diol . Conversion of an achiral or meso compound to an enantiorich chiral product by destructing the C 2 symmetry is known to be one of the highly challenging steps in such a desymmetrization reaction .…”

“…[1] Nadolol, the wellknown β-blocker, contains a meso diol. [2] Conversion of an achiral or meso compound to an enantiorich chiral product by destructing the C 2 symmetry is known to be one of the highly challenging steps in such a desymmetrization reaction. [3] Desymmetrized diols are generally obtained by implying biocatalysis, for example, BCL (Burkholderia capacia lipase) enzyme.…”

Separação, obtenção e utilização de enantômeros puros no controle estereoespecífico de qualidade de medicamentos contendo bisoprolol

“…Os dados disponíveis na literatura sobre a atividade farmacológica dos -bloqueadores indicam que a interação destes agentes com receptores -adrenérgicos é altamente estereoespecífica (43,49,73) . Normalmente, a atividade -bloqueadora cardíaca é devida ao isômero S, sendo que a razão de atividade entre os enantiômeros pode ser altamente variável.…”